Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
Target Oncol. 2010 Sep;5(3):217-27. doi: 10.1007/s11523-010-0151-8. Epub 2010 Aug 25.
Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer stem cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation resistance. Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context of the immunosuppressive properties mediated by the gCSC. Recent findings have indicated that this goal will be challenging because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane interactions. In this review article, we will attempt to reconcile the disparate research findings regarding the potential of immune targeting of the gCSC and propose several novel solutions.
多形性胶质母细胞瘤（GBM）是一种致命的癌症，对放疗和化疗反应不佳。已经表明，神经胶质瘤癌症干细胞（gCSC）能够重现 GBM 的特征，并介导化疗和辐射抵抗。针对该细胞群体的免疫治疗具有治疗潜力，但必须考虑到 gCSC 介导的免疫抑制特性。最近的研究结果表明，这一目标具有挑战性，因为 gCSC 可以通过各种 gCSC 分泌产物和细胞膜相互作用来抑制固有和适应性免疫系统。在这篇综述文章中，我们将尝试调和关于免疫靶向 gCSC 的潜力的不同研究结果，并提出几种新的解决方案。
